Showing results (51-60 of 81) with videos related to
Sort By:
Pageof 9
The Pharmacogenomics Journal|June 27, 2012
Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6N González-Vacarezza, F Abad-Santos, A Carcas-Sansuan, et al.The Pharmacogenomics Journal|August 13, 2014
A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstancesE Peñas-Lledó, S Guillaume, M E G Naranjo, et al.Journal of Clinical Psychopharmacology|December 10, 1999
Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patientsJ A Carrillo, S I Ramos, A G Herraiz, et al.Actas Espanolas De Psiquiatria|December 19, 2002
[Relationship between clozapine plasma levels and withdrawal symptoms]R Berecz, A de la Rubia Martínez, M J Norberto Gamero, et al.European Journal of Clinical Pharmacology|January 1, 1989
Acetylator polymorphism in Parkinson's diseaseJ M Ladero, F J Jimenez, J Benitez, et al.Anatomia, Histologia, Embryologia|May 19, 2015
Development of the Liver in Alpaca (Vicugna pacos): A Microscopic and Macroscopic DescriptionA N C Castro, M T Domínguez, S A Gómez, et al.Pharmacogenomics|November 6, 2025
Implementation of clopidogrel pharmacogenetics: a Brazilian perspectiveJ F Vieira, I H Tassoni, M L Chaves, et al.The Pharmacogenomics Journal|May 12, 2010
CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and SpaniardsP Dorado, M G Sosa-Macias, E M Peñas-Lledó, et al.Journal of Neurology, Neurosurgery, and Psychiatry|April 1, 1990
Oxidative polymorphism of debrisoquine in Parkinson's diseaseJ Benitez, J M Ladero, F J Jimenez-Jimenez, et al.American Journal of Otolaryngology|August 2, 2022
Localized laryngeal amyloidosis: A systematic reviewKavya K Pai, Ariel O Omiunu, Pablo A Llerena, et al.Pageof 9